This product is an angiotensin II receptor antagonist. This product can selectively act on the AT1 receptor subtype known to be related to the action of angiotensin II, selectively block the binding of angiotensin II to the AT1 receptor of tissue cells such as the adrenal glands and vascular smooth muscle, inhibit vasoconstriction and aldosterone secretion, and produce a hypotensive effect. The affinity of this product for AT1 receptors is about 20,000 times higher than that for AT2 receptors. This product does not affect the action of bradykinin and ion channel function, nor does it bind to the receptors of other hormones that play an important regulatory role in cardiovascular function. This product has no carcinogenic, teratogenic, mutagenic toxicity, and no reproductive toxicity.

This product is an angiotensin II receptor antagonist. This product can selectively act on the AT1 receptor subtype known to be related to the action of angiotensin II, selectively block the binding of angiotensin II to the AT1 receptor of tissue cells such as the adrenal glands and vascular smooth muscle, inhibit vasoconstriction and aldosterone secretion, and produce a hypotensive effect. The affinity of this product for AT1 receptors is about 20,000 times higher than that for AT2 receptors. This product does not affect the action of bradykinin and ion channel function, nor does it bind to the receptors of other hormones that play an important regulatory role in cardiovascular function. This product has no carcinogenic, teratogenic, mutagenic toxicity, and no reproductive toxicity.

This product is a glipizide controlled-release tablet designed according to a special gastrointestinal therapeutic system (GITS). It is wrapped by a semipermeable membrane and contains glipizide and a non-pharmacologically active ingredient that can absorb water. The tablet swells after absorbing water, and glipizide is released from the small holes punched by the laser. Two hours after oral administration, the active ingredient (glipizide) begins to be released stably, which can be maintained for about 8 hours. The release rate gradually decreases, and the release is completed about 16 hours after taking the medicine. The elimination half-life of glipizide gradually absorbed into the blood in the intestine is about 2.5 to 4 hours. The blood drug concentration can be maintained within 24 hours after taking the medicine. After taking 5 mg orally once, the average blood drug concentration in 24 hours can reach more than 50ng/ml. Taking the medicine once a day can control blood sugar throughout the day. After taking the medicine for 5 days, the blood drug concentration reaches a steady state, and it takes 6 to 7 days for elderly patients to reach a steady state.

This product is a glipizide controlled-release tablet designed according to the special gastrointestinal therapeutic system (GITS). It can maintain stable release for about 8 hours, and then the release rate gradually decreases until the release is completed about 16 hours after taking the medicine. The elimination half-life of glipizide gradually absorbed into the blood in the intestine is about 2.5 to 4 hours. It can maintain a relatively stable blood drug concentration within 24 hours after taking the medicine. After taking 5 mg orally once, the average blood drug concentration in 24 hours can reach more than 50ng/ml. Taking the medicine once a day can control blood sugar throughout the day.

1. It can simultaneously relax the coronary arteries in the normal blood supply area and the ischemic area, antagonize spontaneous or ergonovine-induced coronary artery spasm, increase the delivery of myocardial oxygen to patients with coronary artery spasm, and relieve and prevent coronary artery spasm. 2. It can inhibit myocardial contraction, reduce myocardial metabolism, and reduce myocardial oxygen consumption. 3. It can relax peripheral resistance vessels, reduce peripheral resistance, and can reduce systolic and diastolic blood pressure, reducing cardiac afterload. 4. It can delay the sinus node function and atrioventricular conduction of isolated hearts; electrophysiological studies of whole animals and humans have not found any effect of delaying atrioventricular conduction, prolonging sinus node recovery time, and slowing down sinus node rate.